Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.
Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M. Miura Y, et al. Among authors: minato k. Oncol Lett. 2017 Aug;14(2):2369-2378. doi: 10.3892/ol.2017.6419. Epub 2017 Jun 19. Oncol Lett. 2017. PMID: 28789453 Free PMC article.
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Kaira K, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19. Cancer Chemother Pharmacol. 2017. PMID: 27995307 Clinical Trial.
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Imai H, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6. Cancer Chemother Pharmacol. 2017. PMID: 28168310 Free PMC article.
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T. Kaira K, et al. Among authors: minato k. Anticancer Res. 2019 May;39(5):2483-2491. doi: 10.21873/anticanres.13368. Anticancer Res. 2019. PMID: 31092443 Clinical Trial.
Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H, Kaira K, Mori K, Kotake M, Mitani M, Kawashima N, Hisada T, Minato K. Imai H, et al. Among authors: minato k. Thorac Cancer. 2019 Dec;10(12):2200-2208. doi: 10.1111/1759-7714.13193. Epub 2019 Oct 8. Thorac Cancer. 2019. PMID: 31595714 Free PMC article.
597 results